13 results
Primary aim: Frequency of identifying CTCs and their numbers in apheresis product before and after (during) treatment.Secondary aim: Prediction of response to therapy in different stages of NSCLC patient groups with the change in CTC numbers.
Identification of protein profile differences between laryngeal cancer of young and elderly patients. Secondary objective is to identify differences between protein interaction network in cancer and healthy tissue in young and elderly laryngeal…
The primary objective is to establish the neuroprotective efficacy of NAC against cisplatin-induced neurotoxicity. Mainly the sensory neuronal guidance will be assessed before and after treatment with cisplatin in a group of patients receiving NAC…
2.1 Primary objectives Primary objective is scientific research to study the additional effect of bevacizumab on hypoxia related parameters. 2.2 Secondary objectives a) To compare the efficacy of bevacizumab with pre-treatment obtained values of…
The primary objective is to evaluate the percentage of the study population who have OSAS before and after treatment and the severity of it. A second objective is to correlate the prevalence of OSAS with different tumour sites and stages, as well as…
To investigate the newly developed method to study lung density changes using CT-scan, in a small patient population. The relationship between radiation induced lung density changes and dose distribution/tumor location will be investigated.
The aim is to investigate whether it is feasible to perform a 12-weeks nutritional intervention study in NSCLC patients on PD-1 ICI, and to effectively assess their nutritional, immune, and microbial status, with the intention to use this…
This is an exploratory study to assess the presence, specificity, type and strength of systemic and local specific cellular immune responses in patients with lung adenocarcinoma at different time-points during routine diagnostic work-up and…
We aim to optimize the radiation treatment of early stage lung cancer patients. Cardiac sparing is possible, but it comes at the cost of an increased mean lung dose. Without proof of cardiac toxicity, cardiac sparing will not be (routinely) applied…
By an early-initiated personal, supportive care program prevent deterioration of performance status (=WHO 0 or 1) in at least 90% of patients with NSCLC stage III, as determined by the patient itself, at the start of immunotherapy.
Identify molecular differences in carcinogenesis of LSCC between younger and elderly patients through an integrated proteogenomic analysis of laryngeal tissue biopsies that could optimize personalized treatment of elderly patients in particular.
To assess memory function at 4 months after Hippocampus Avoidance-PCI versus standard whole brain PCI
Mortality will be lower in patients who do not smoke during treatment of non-small cell lung carcinoma with PD-L1-inhibitors compared to patients who smoke during their treatment with PD-L1-inhibitors.